Call Us: 1.800.873.5297


FDA Approves Qutenza for PHN

NeruogesX Inc. announced in November that the Food and Drug Administration has approved Qutenza (capsaicin) 8% patch for the management of neuropathic pain as a result of postherpetic neuralgia (PHN). This is the only product to be approved so far that contains prescription strength capsaicin.

PHN is nerve pain that can occur following shingles. Shingles can damage nerves and the pain from this nerve damage is sharp, burning, tingling shooting or even numb in sensation. It can persist after the attack of shingles has cleared up disrupting the life of the victim. The risk of PHN increases with age and in those who experienced sharp pain or a severe rash during the episode of shingles.

Qutenza delivers medication through a dermal delivery system to provide up to three months of pain relief after a single hour application. The nerves are targeted in the area of skin where the patient feels pain. The patch is applied by a healthcare professional and up to four patches may be used at the same time. Reports state it is a non-narcotic, locally acting and will not cause drowsiness or have adverse drug interactions.

Common side effects during clinical trials include:

  • Pain
  • Itching
  • Site redness
  • Papules

Serious adverse reactions included application site pain and increased blood pressure. Blood pressure increases occurred during or just after exposure to Qutenza and lasted for around two hours after the patch was removed.

If you or a loved one has taken Qutenza and developed these or other adverse reactions, please contact the experienced pharmaceutical litigation attorneys at Schlichter, Bogard & Denton today for a case consultation. We serve the Kansas City, Missouri area, as well as clients nationwide.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.